34 Unique Listed Chemical Reagents in 5 g qty with Purity >95%
COMBINED SYNOPSIS / SOLICITATION COVID 19- Action Title: 34 unique listed chemical reagents in 5 g qty with purity >95% (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95022Q00177 and the solicitation is issued as a Request for Quote (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition teshold. This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; FAR Subpart 13.5— Simplified Procedures for Certain Commercial Items; and FAR Part 12—Acquisition of Commercial Items, and is expected to exceed the simplified acquisition teshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect tough Federal Acquisition Circular (FAC) Number 2022-04, with effective date January 30,2022. (iv) The associated NAICS code 325412 and the small business size standard is 1,250 employees. This requirement is set-aside to small business interests. (v) Set-aside Status: Small Business Set Aside (vi) Competition Status: This requirement is posted as competitive DESCRIPTION Quantity: 32 compounds listed below each 5 g qty Structures Name Smiles 4-((2-aminoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCN)=C31)=O 4-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCCCN)=C31)=O 4-((6-aminohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCCCCCN)=C31)=O 4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCCCCCCCN)=C31)=O 4-((2-(2-aminoethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCN)=C31)=O 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCOCCN)=C31)=O 4-((2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCOCCOCCN)=C31)=O 4-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCOCCOCCOCCN)=C31)=O (2S,4R)-1-((S)-2-(3-aminopropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-2-(5-aminopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-2-(7-aminoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCCCCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-2-(9-aminononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCCCCCCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-2-(2-(2-aminoethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-2-(2-(2-(2-aminoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-14-amino-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCOCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-17-amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCOCCOCCN)=O)C(C)(C)C)=O (2S,4R)-1-((S)-20-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCOCCOCCOCCN)=O)C(C)(C)C)=O 4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCC(O)=O)=O)C(C)(C)C)=O 6-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexanoic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCCCC(O)=O)=O)C(C)(C)C)=O 8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-8-oxooctanoic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCCCCCC(O)=O)=O)C(C)(C)C)=O 10-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-10-oxodecanoic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(CCCCCCCCC(O)=O)=O)C(C)(C)C)=O 2-(2,6-dioxopiperidin-3-yl)-4-((2-(hydroxy-l2-methoxy)ethyl)amino)isoindoline-1,3-dione O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCO[C]O)=C31)=O 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCCCC(O)=O)=C31)=O 7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCCCCCC(O)=O)=C31)=O 9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)nonanoic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCCCCCCCC(O)=O)=C31)=O 3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCC(O)=O)=C31)=O 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCOCCC(O)=O)=C31)=O 3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCOCCOCCC(O)=O)=C31)=O 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oic acid O=C1N(C2C(NC(CC2)=O)=O)C(C3=CC=CC(NCCOCCOCCOCCOCCC(O)=O)=C31)=O 3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)propanoic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCC(O)=O)=O)C(C)(C)C)=O 3-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)propanoic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCC(O)=O)=O)C(C)(C)C)=O (S)-3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5-oxo-7,10,13-trioxa-4-azahexadecan-16-oic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCOCCC(O)=O)=O)C(C)(C)C)=O (S)-3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCOCCOCCC(O)=O)=O)C(C)(C)C)=O (S)-3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5-oxo-7,10,13,16,19-pentaoxa-4-azadocosan-22-oic acid O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@@H](NC(COCCOCCOCCOCCOCCC(O)=O)=O)C(C)(C)C)=O Salient characteristics: • 5 g qty with purity >95% as characterized by mass spec and NMR data. • All the compounds from this set must come from one source/laboratory where they are synthesized and characterized in the same fashion and similar environments. • All compounds should be shipped as one package within 12 weeks after receiving the purchasing order. • All 5 g quantity must be from the same batch and must be shipped in a single vial. • All compounds should be provided with LCMS and NMR data. (vii) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated delivery date is 12 weeks after receipt of order (ARO). Delivery will be f.o.b. destination. The place of delivery and acceptance will be 9800 Medical Center Drive, Building B, Rockville, MD 20850. The Government is requiring that the compounds be delivered in ONE delivery only. (viii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: • FAR 52.204-7, System for Award Management (Oct 2018) • FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) • FAR 52.212-1, Instructions to Offerors-Commercial Items (Nov 2021) • FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021) • FAR 52.225-2, Buy American Certificate (Feb 2021) • FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate (Feb 2021) • 52.212-5 attachment, then also include Alternate I, II, or III (Feb 2021) • FAR 52.225-6, Trade Agreements Certificate (Feb 2021)> • HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html The following clauses apply to this acquisition and are incorporated by reference: • FAR 52.204-13, System for Award Management Maintenance (Oct 2018) • FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) • FAR 52.212-4, Contract Terms and Conditions--Commercial Items (Nov 2021). Addendum to this FAR clause applies to this acquisition and is attached. • HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) • HHSAR 352-232-71 Electronic Submission of Payment Requests (FEB 2022) • FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Items (Jan 2022) • NIH Invoice and Payment Provisions (Feb 2021) • Notice of Total Small Business Set-Aside (Mar 2020) EVALUATION (ix) The Government may perform a comparative evaluation of responses in accordance with FAR 13.106-2(b) to select the contractor that is best suited and provides the best value, considering the evaluation factors in this solicitation. The evaluation will compare: Technical capability of the item offered to meet the Government requirement in accordance with the salient characteristics specified in the Purchase Description, Price, and Past Performance as defined under FAR 13.106-2(b)(3). If only one quotation is received it will be evaluated on the preceding. The government reserves the right to select a response that provides benefit to the government that exceeds the minimum; the government is not required to select a response that exceeds the minimum; responses may exceed the requirements; each response must meet the solicitation requirement statement at a minimum; and the government is not requesting or accepting alternate proposal(s). (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi) The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Nov 2021), applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. (xii) The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices. (xiii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. SUBMISSION INSTRUCTIONS (xiv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Quote must include shipping and handling costs to provide single delivery of compounds to NCATS. The Unique Entity ID from SAM.gov, UEI Number, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must submit a Buy American Certificate and TAA Compliance Certificate with their quote. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All questions must be received by 11:00 a.m., EST, on April 15, 2022, and reference Solicitation Number 75N95022Q00177. Questions may be submitted electronically to Michelle Cecilia, Contracting Officer, at michelle.cecilia@nih.gov. All quotations must be received by 3:00 p.m., EST, on April 22, 2022, and reference Solicitation Number 75N95022Q00177. Responses must be submitted electronically to Michelle Cecilia, Contracting Officer, at Michelle.cecilia@nih.gov. Fax responses will not be accepted. (xv) The name and telephone number of the individual to contact for information regarding the solicitation: Michelle Cecilia Contract Officer Phone: (301) 827-7199 Email: michelle.cecilia@nih.gov ATTACHMENTS • Purchase Description • FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes Executive Orders–Commercial Items (Jan 2022) • NIH Invoice and Payment Provisions (Feb 2021) • FAR 52.212-4_Addendum_Supplier_LicensesRevised: February 10, 2021 75N95022R00040 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
4/13/22, 11:59 AM Annual Subscription and Bronze Support for E-Notebook Enterprise Oracle Pro
PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE Notice of Intent: 75N95022R00040 INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE- SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisitions, Contracts Management Branch Blue, NCATS Section on behalf of the National Center for Advancing Translational Sciences intends to negotiate and award a contract for Annual Subscription and Bronze Support for E-Notebook Enterprise Oracle Pro. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS Code 541511: Custom Computer Programming Services: Size Standard of $30.0 million. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Regulation (FAR) in effect tough the Federal Acquisition Circular 2022-02, dated January 30, 2022. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source. DESCRIPTION OF REQUIREMENT Project Description NCATS is in need of obtaining a one (1) year license of an electronic notebook to be used by the chemists within the Center to capture their experiments. The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The NCATS Early Translation Branch (ETB) is tasked with identifying and developing novel small molecule leads against a wide spectrum of human disease targets, which it accomplishes by screening thousands of small molecules in collaboration with both intra-and extramural researchers. In pursuit of this goal, the Center has a strong internal transdisciplinary team of scientists who continually discover novel small molecules for application against a wide range of human diseases. As such, NCATS is in need of an annual subscription to E-Notebook to be used to in everyday activities of all chemists at the Center to capture their experiments. General Requirements Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified, personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the requirements in the Product Description: 20 ea AEN-ENTRPRO-ESP Bronze Support for E-Notebook Enterprise Oracle Pro. provides upgrades to feature enhanced future versions of the software product initially licensed, as well as corrective software updates, and more. 20 ea. AEN-ENTRESP Bronze Support for E-Notebook Enterprise Oracle Ultra provides upgrades to feature enhanced future versions of the software product initially licensed, as well as corrective software updates, and more. This request to Perkin Elmer will allow us to renew our software subscription to our currently in-use Electronic Laboratory Notebook equipment to current standards, which will create better security and efficiency. Vendor is responsible for delivering access to an electronic notebook software that fulfills the following requirements: 1. Software should have ChemBioDraw embedded in the E-Notebook to enable chemists to create reaction schemes with starting materials, catalysts, reagents and products. 2. Allow for the automatic generation of IUPAC names and stoichiometry tables. 3. Integration with tools such as Microsoft Office documents, spreadsheets, presentations, PDF and other image files to allow chemists to efficiently incorporate materials from a variety of sources 4. Provide a chemically-oriented Autotext feature. 5. It should be able to handle singleton chemistry and parallel syntheses and can enumerate the products from generic reactions and lists of reagents in a chemically intelligent way. Purchase Description See Attached Period of Performance The period of performance is as follows: Base Year: 3/26/2022 tough 03/25/2023 Option Year 1: 3/26/23 tough 3/25/24 Option Year 2: 3/26/24 tough 3/25/25 Option Year 3: 3/26/25 tough 3/25/26 CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. The respondents must submit clear and convincing evidence that their product is equivalent or superior to the product specified in this notice. The response shall include: the unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered to determine the method of acquisition. The response must also indicate the country of manufacturer of components and country of assembly (not necessary for IT purchases). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non- competitive basis or to conduct a competitive procurement. All responses must be received by March at 15, 2022 at 11:00 AM Eastern Time and must reference number 75N95022R00040. Responses must be submitted electronically to Michelle Cecilia, Contract Specialist, at michelle.cecilia@nih.gov, and must reference the solicitation number 75N95022R00040, on your electronic request. FAX requests are not accepted. “All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.” 75N95022R00040 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
3/8/22, 3:47 PM